Bluetongue outbreak endangers UK livestock – what you need to know about the virus
As of July 1, the whole of England has been classed as an 'infected area' due to bluetongue virus serotype 3 (BTV-3).
There are movement restrictions and testing in place in Scotland, Wales and the island of Ireland. No animals from England – or that have passed through England – are allowed to attend this year's Royal Welsh Show on July 21-24, for example.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
The virus, which causes illness and death in sheep, cattle, goats and other ruminants, is spread by biting midges. Although it poses no risk to humans and can't be transmitted from one animal to another, the latest outbreak is more severe than previous ones. And it could cause lasting damage to UK farming.
Bluetongue isn't new to the UK, however. A different strain, BTV-8 was detected in 2007 and contained. But BTV-3 is a different story. First detected in the Netherlands in late 2023, it was quickly spotted in the UK, where an early containment effort initially appeared successful.
But the virus made a comeback in autumn 2024 – and this time it spread. On its second attempt, the virus was able to circulate and caused an outbreak. With little existing immunity, BTV-3 has now established itself, prompting concerns about animal welfare, food production and farming livelihoods.
What does the disease do?
Sheep tend to be the most severely affected, though all ruminants are at risk. Clinical signs are species-specific but can include swelling of the face, congestion, nasal discharge, ulcers in the mouth and nose, difficulty breathing and abortion or birth deformities.
Bluetongue can cause the animal's tongue to swell. It can also turn blue from lack of blood flow – although this is somewhat rare.
Bluetongue disease causes suffering in animals, and while there is a vaccine, there is no treatment for the disease once it's contracted.
BTV-3 appears to be more lethal than earlier strains. In the Netherlands, vets report that BTV-3 is causing more severe symptoms than BTV-8 did.
Vets in England reported that in some herds 25-40% of cows failed to get pregnant, and there was a high rate of birth defects and stillborn calves. One farm in Suffolk started the calving season with 25% of their cows not pregnant and ended with just 48 calves from 97 cows.
Belgium has seen a fall in calf births, reduced milk deliveries and higher mortality in small ruminants compared to the previous three years.
How is it spread?
Bluetongue virus is transmitted by midges from the Culicoides genus. These are tiny, biting insects that thrive in mild, wet conditions.
Multiple midges can bite the same animal, and it only takes one of them to carry BTV before that animal becomes a host for further transmission. When animals are transported long distances, infected individuals can be bitten again and introduce the virus to previously uninfected midge populations.
Climate change is making outbreaks like this more likely. Milder winters and cooler, wetter summers are ideal for midges, increasing both their numbers and their biting activity.
While there's no danger to human health, the consequences of BTV-3 are far-reaching. Limitations on movement, exports and imports are being imposed to help prevent the spread of the disease, but this could also hamper farming practices and trade.
The disease and its associated restrictions pose another source of stress for farmers, 95% of whom have ranked mental health as the biggest hidden problem in farming.
Genetic pick and mix
One of the reasons bluetongue is so tricky to manage is its ability to evolve. It has a segmented genome, meaning its genetic material, in this case RNA, is split into ten segments. This characteristic is exclusive to 'reassortment viruses' and means that they can easily exchange segments of RNA. It's like a genetic pick and mix with ten different types of sweets that come in an unlimited number of flavours.
This allows BTV to create new, genetically distinct 'serotypes', which may have a selective advantage or a disadvantage. Those with an advantage will emerge and spread successfully, while those with a disadvantage will not emerge at all. This process, known as 'reassortment', is partly responsible for the numerous influenza pandemics throughout history and has even allowed diseases to jump the species barrier.
Although bluetongue doesn't affect humans directly, its spread poses a growing threat to the UK's livestock sector and food supply. It's important to learn from other countries that are further along in the BTV-3 outbreak so that the likely effects can be anticipated in the UK.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Cate Williams does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
The impact strike action by hospital doctors had on Bolton patients
Dozens of appointments and procedures had to be cancelled in Bolton after resident doctors went on strike in Bolton last week. Bolton NHS Foundation Trust detailed the number at its board meeting, which was held just after the strike action. The latest strike began last week amid an ongoing row over pay. Resident doctors, previously known as junior doctors, went on strike demanding a 29 per cent pay rise and have since been locked in industrial action with the government, which has refused to negotiate on pay. Hospital leaders have since called on the British Medical Association (BMA) and the Government to end the strikes after five days of disruption across the NHS in England. The Royal Bolton Hospital was among those affected by the industrial action. Figures have revealed the NHS maintained care for an estimated 10,000 more patients during the latest doctors' strike compared with last year's industrial action. READ MORE: NHS maintained 93% of planned care during resident doctors' strikes Bolton patient calls on hospital to rethink decision over cutting sandwiches Bolton patients given advice what to do during doctors' strike Nationally, data shows that 93 per cent of planned operations, tests and procedures went ahead during the five-day walkout across England. Chief Operating Officer Bolton NHS Foundation Trust, Rae Wheatcroft said: 'As a result of the strike action, Royal Bolton NHS Foundation Trust have had to cancel 58 outpatient appointments and 32 procedures over the course of the five days. 'The action has had an impact and will continue to have an impact on our longer waiting patients unfortunately. 'The longer waiting patients are lower risk patients, and therefore they are the ones that have been cancelled in some instances. 'It will depend on whether there is further action as to how this transpires. 'The financial impact of the strikes will depend on the decisions we take as early warning indicators. If we see the waiting list change direction, which has been reducing for the past 12 months. 'If this changes direction, that will be an early indicator, and we will know to take action.' Nationally, in previous walkouts, the majority of non-urgent care was postponed. Fewer than a third of resident doctors, previously known as junior doctors, chose to join the strike, which ended on Wednesday morning. The number was down by 7.5 per cent (1,243) on the previous round of industrial action in July last year, according to the early analysis of management information collected by NHS England. The BMA said it recognised the efforts that senior doctors and healthcare workers made during the strike to provide care to patients, but it disputed the figure set out by the NHS. It said: 'NHS England's claim that the majority of England's 77,000 resident doctors chose to 'join the NHS-wide effort to keep the services open' requires a huge stretch of the imagination, given it is almost impossible to know the exact number of residents working on any given day because of complex work patterns, on-call schedules and the strike spread across a weekend. "Added to that, in July many doctors are using up their remaining annual leave before their new posts start and would therefore not show up as striking. 'We look forward to seeing hard and fast data on NHS England's claim. "The strike could have been averted, as could any future ones, if Mr Streeting had come, and will come, to the table with a credible offer that resident doctors in England can accept.'
Yahoo
13 minutes ago
- Yahoo
Warning over serious virus affecting newborns after surge in cases
Britain should prepare for a surge in a potentially serious virus following a record number of cases in Australia, health experts have warned. NHS officials said the Australian winter is often a reliable indicator of how viruses will spread in the UK. Following a spike in respiratory syncytial virus (RSV) cases in Australia, officials have confirmed that cases have been steadily rising in England since the beginning of 2025. NHS England has encouraged pregnant women to receive the vaccine which guards against RSV in order to protect their newborn babies. The health service said the virus is a leading cause of death among babies and the primary cause of hospital admissions for children. READ MORE: Girl, four, dies after incident at water park READ MORE: Full list of air fryers recalled as households told 'stop using' Kate Brintworth, chief midwifery officer for NHS England, said: "While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation. "Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating." Expectant mothers can receive the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery. Older adults aged 75-79 are also eligible for the vaccination and NHS England will begin inviting people to come forward in the coming weeks. RSV is a frequent cause of coughs and colds. However, certain individuals, including infants and adults over the age of 75, are at high risk of becoming seriously ill from the virus. In infants, RSV is a common cause of a chest infection known as bronchiolitis. Last week, data demonstrating the effectiveness of the vaccine was published by the UK Health Security Agency. The agency stated that the jab for expectant mothers can prevent 72% of hospital admissions for their babies. Furthermore, the vaccine is 82% effective at preventing hospital admissions for RSV among older adults, according to the UKHSA. For the latest news and breaking news visit Get all the big headlines, pictures, analysis, opinion and video on the stories that matter to you by signing up to our daily and breaking newsletter. Sign up to our breaking news newsletter here. Follow us on X @LivECHONews or on Bluesky @ - official Liverpool ECHO accounts - real news in real time. We're also on Facebook/theliverpoolecho - your must-see news, features, videos and pictures throughout the day from the Liverpool ECHO.
Yahoo
4 hours ago
- Yahoo
These medications could save thousands of lives – but doctors aren't prescribing them
In 2021, varenicline, the most effective single drug for quitting smoking, was withdrawn from the market in the UK because impurities were found at greater levels than is considered safe. Rapidly, varenicline (then sold under its brand names, Champix and Chantix) became unavailable. This was a disaster for public health. Research from University College London estimated that varenicline being unavailable resulted in about 1,890 more avoidable deaths each year because fewer people were successfully quitting smoking. But there was hope. Cytisine (also known as cytisinicline), a naturally occurring plant-based product that had been used for decades in Eastern Europe, and more recently to great effect elsewhere in the world, was licensed in the UK and made available from January 2024. Even so, there was an extended period when neither were available to people trying to quit smoking in the UK (and in other countries, too). But in the UK at least, things were looking up. Based on a limited but growing body of evidence, cytisine probably works as well as varenicline at helping people quit smoking, and it may be better tolerated with fewer side effects. It may also appeal to more smokers who may want to use a natural product rather than a drug designed in a lab. So, with varenicline withdrawn and a similarly effective treatment available, we should have seen lives saved as people who would have taken varenicline were encouraged to try cytisine instead. Why isn't anyone prescribing it? This didn't happen. Cytisine – despite now being licensed and available in the UK – is still shockingly underused. Since January 2024, only 0.2% of people trying to quit smoking have used it (the same proportion that used it in 2018, when it wasn't even officially available in the UK). Official NHS data from people accessing stop-smoking services in England confirm that only 0.7% were prescribed cytisine in 2024. So why is this? High-profile trials continue to show cytisine's effectiveness for quitting smoking (and even for quitting vaping). Maybe cytisine's relatively complex dosing schedule puts people off. Cytisine starts with six pills a day (one every two hours) and gradually tapers off over a few weeks: more confusing and less convenient than one-a-day varenicline. Another possibility is that the public's attention has shifted. With so much focus in recent years on vaping as a smoking cessation aid, prescription drugs for smoking cessation may have fallen off the radar. It could also be that GPs are reluctant to prescribe cytisine because of its cost and the assumption that local authorities should pay for it, not primary care. While it was once hoped that due to its low-cost availability in Eastern Europe, it would become the 'aspirin of smoking cessation drugs', the licensed product in the UK is now as or more expensive than other drugs. But the simplest explanation is probably the most accurate: not enough people know about cytisine. People who smoke, GPs, pharmacists and even stop-smoking services may not know it's an option. And if no one is talking about it, no one is prescribing it. And even if they do know about it, there may be a lack of confidence in using or prescribing it because it is a new drug. That's a problem. The UK government has made the shift from treating illness to preventing it a central part of its health strategy. Smoking remains the leading cause of preventable death in the country and the world. If we're serious about prevention, then effective smoking cessation support must be top of the agenda. Now, varenicline is available again (without its brand names and reformulated to remove the impurities). This is welcome news, but only 1.1% of past-year smokers reported using varenicline. That's only a quarter of the number from before its withdrawal. This raises an important question: should we return to prescribing varenicline by default, or is it time to consider cytisine as a first-line treatment? Researchers are continuing to learn more about cytisine, but as the evidence in favour of cytisine grows, maybe it needs a PR campaign for both prescribers and people who smoke. None of this is to say that cytisine is a miracle cure, or that it will work for everyone. But that's true of every way to help people quit smoking. Quitting smoking is hard, and people trying to quit need more options, not fewer, and those options need to be visible and accessible. Jonathan Livingstone-Banks is a Lecturer & Senior Researcher in Evidence-Based Healthcare at the University of Oxford. Dimitra Kale is a Senior Research Fellow in Health Psychology at UCL. Lion Shahab is a Professor in Health Psychology at UCL. This article is republished from The Conversation under a Creative Commons license. Read the original article.
